In AD, progressive amyloid and tau pathology affect frontal and parietal structures, potentially amplifying the effects of MSE disrupting executive and integrative processes related to cognitive, functional, and neuropsychiatric impairments33–35. Here, MAPT is linked to amyloidosis.